CymaBay Therapeutics, Inc. (Nasdaq: CBAY) announced that after receiving input from the U.S. Food and Drug Administration (FDA), it has ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE